HC Wainwright Has Negative Outlook of Personalis Q2 Earnings

Personalis, Inc. (NASDAQ:PSNL - Free Report) - Analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for Personalis in a research note issued on Wednesday, May 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.26) per share for the quarter, down from their previous forecast of ($0.23). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Personalis' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Personalis' Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.00) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.62) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at $0.02 EPS.

Personalis (NASDAQ:PSNL - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%.

Other equities research analysts have also recently issued research reports about the stock. Craig Hallum assumed coverage on shares of Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $7.00 target price on shares of Personalis in a report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $8.00.

Personalis Trading Up 0.8%

Shares of PSNL stock traded up $0.04 on Monday, hitting $5.14. 526,884 shares of the stock were exchanged, compared to its average volume of 1,003,315. The firm has a market capitalization of $453.99 million, a PE ratio of -3.06 and a beta of 1.83. Personalis has a one year low of $1.14 and a one year high of $7.20. The firm's 50 day moving average is $3.70 and its two-hundred day moving average is $4.46.

Hedge Funds Weigh In On Personalis

Large investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Personalis in the 4th quarter worth about $28,000. JPMorgan Chase & Co. increased its stake in Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after acquiring an additional 5,654 shares during the last quarter. Olympiad Research LP bought a new position in Personalis in the 4th quarter worth about $59,000. Alpine Global Management LLC bought a new position in Personalis in the 4th quarter worth about $60,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Personalis by 18.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after acquiring an additional 2,724 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.